Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: A matched analysis

Clinical Transplantation

Volumn 29, Issue 9, 2015, Pages 813-819

  Saab, Sammy ^a   Jimenez, Melissa ^a   Bau, Sherona ^a   Goo, Tyralee ^a   Zhao, Difan ^a   Durazo, Francisco ^a   Han, Steven ^a   El Kabany, Mohammed ^a   Kaldas, Fady ^a   Tong, Myron J ^a,b   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Antiviral therapy; Fibrosing cholestatic hepatitis; Hepatitis C; Liver transplant; Patient survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; MYCOPHENOLATE MOFETIL; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; FIBROSING CHOLESTATIC HEPATITIS C; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT; LIVER GRAFT REJECTION; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT OUTCOME; CASE CONTROL STUDY; CHOLESTASIS, INTRAHEPATIC; COMBINATION DRUG THERAPY; EVALUATION STUDY; FOLLOW UP; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIDDLE AGED; MORTALITY; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHOLESTASIS, INTRAHEPATIC; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84940956189     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12584     Document Type: Article

References (50)

1. Kim WR, Lake JR, Smith JM et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015: 15(Suppl 2): 1.
2. Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004: 77: 226.
3. Busuttil RW, Farmer DG, Yersiz H et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005: 241: 905.
4. Gallegos-Orozco JF, Yosephy A, Noble B et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009: 15: 1872.
5. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013: 58: 1028.
6. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998: 4: 304.
7. Pessoa MG, Bzowej N, Berenguer M et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999: 30: 1513.
8. Cotler SJ, Taylor SL, Gretch DR et al. Hyperbilirubinemia and cholestatic liver injury in hepatitis C infected liver transplant recipients. Am J Gastroenterol 2000: 95: 753.
9. Dixon L, Crawford J. Early histological changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007: 13: 219.
10. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010: 16: 1228.
11. Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013: 19: 78.
12. Salomao M, Verna EC, Lefkowitch JH, Moreira RK. Histopathologic distinction between fibrosing cholestatic hepatitis C and biliary obstruction. Am J Surg Pathol 2013: 37: 1837.
13. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998: 4: 15.
14. Deshpande V, Burd E, Aardema KL et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 2001: 7: 118.
15. Fukuhara T, Morita K, Takeishi K et al. Early diagnosis and treatment resolved cholestatic hepatitis C without fibrosis after living donor liver transplantation: report of a case. Surg Today 2010: 40: 982.
16. Cimsit B, Assis D, Caldwell C et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc 2011: 43: 905.
17. Antonini TM, Sebagh M, Roque-Afonso AM et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011: 11: 1686.
18. Antonini TM, Furlan V, Teicher E et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015: 29: 53.
19. Murakami K, Kawagishi N, Ishida K et al. Fibrosing cholestatic hepatitis developing within one month after living donor liver transplantation for chronic hepatitis C-related cirrhosis: a case report. Transplant Proc 2014: 46: 995.
20. Ong JP, Younossi ZM, Gramlich T et al. Interferon alpha 2b and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001: 71: 1486.
21. Takahashi T, Ashizawa S, Matsumoto H et al. Fibrosing cholestatic hepatitis developing after liver transplantation: case report of a patient with HCV-related cirrhosis. Transplant Proc 2003: 35: 392.
22. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003: 9: 348.
23. Bolkhir A, Blunt E, Solomon H, Hayashi P. Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl 2007: 13: 309.
24. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012: 18: 1053.
25. Antonini TM, Furlan V, Teicher E et al. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft. AIDS 2013: 27: 2655.
26. Coilly A, Roche B, Dumortier J et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014: 60: 78.
27. Werner CR, Egetemeyr DP, Nadalin S et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol 2014: 52: 27.
28. Faisal N, Yoshida EM, Bilodeau M et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014: 13: 525.
29. Delabaudière C, Lavayssière L, Dörr G et al. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int 2015: 28: 255.
30. Al Nahdi N, Ford JA, Greanya ED et al. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol 2013: 12: 156.
31. Saab S, Manne V, Bau S et al. Boceprevir in liver transplant recipients. Liver Int 2015: 35: 192.
32. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011: 54: 20.
33. Kwo PY, Mantry PS, Coakley E et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014: 371: 2375.
34. Charlton M, Gane E, Manns MP et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015: 148: 108.
35. Fontana RJ, Hughes EA, Bifano M et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013: 13: 1601.
36. Kim B, Trivedi A, Thung SN, Grewal P. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis 2014: 34: 108.
37. Borentain P, Colson P, Dhiver C et al. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient. Antivir Ther 2015: 20: 353.
38. Pellicelli AM, Montalbano M, Lionetti R et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014: 46: 923.
39. Forns X, Prieto M, Charlton MM et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. J Hepatol 2014: 60: S26.
40. Saab S, Oh MK, Ibrahim AB et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007: 13: 1032.
41. Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996: 110: 167.
42. Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996: 23: 971.
43. Forns X, Charlton M, Denning J et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2015: 61: 1485.
44. Perumpail RB, Wong RJ, Ha LD et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis 2015: 17: 275.
45. Bhamidimarri KR, Gutierrez J, Grigorian A et al. Urgent treatment with sofosbuvir based regimen for hepatitis C genotype 1 with severe renal insufficiency (GFR <30 ml/min). Am Assoc Study Liver Dis Annu Meet 2014: 688A: 1004.
46. McCombs J, Matsuda T, Tonnu-Mihara I et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014: 174: 204.
47. Kurosaki M, Hiramatsu N, Sakamoto M et al. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis. Antivir Ther 2012: 17: 35.
48. Ogawa E, Furusyo N, Kajiwara E et al. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. J Infect Chemother 2012: 18: 689.
49. Svarovskaia ES, Dvory-Sobol H, Parkin N et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014: 59: 1666.
50. Charlton M, Everson GT, Flamm SL et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015: 148: 108.